Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ready for us to turn the corner guys hopefully our faith is rewarded ..
Thanks sabay for the update. Excellent news, time to take this company seriously.
Alberta Biophotonics Inc. Acquires Additional Shares of Flurotech Ltd. Pursuant to Amalgamation
Calgary, Alberta--(Newsfile Corp. - June 2, 2021) - Alberta BioPhotonics Inc. ("ABP") announces the filing of an early warning report in connection with its acquisition (the "Acquisition") of an additional 12,211,608 common shares in the capital of FluroTech Ltd. ("FluroTech") (the "Shares") effective May 20, 2021, pursuant to a three-cornered amalgamation between the FluroTech, FluroTest Systems Ltd. ("FluroTest") and 2330853 Alberta Ltd., whereby FluroTech acquired all of the shares of FluroTest not previously owned by FluroTech (the "Transaction") in exchange for issuing one Share to ABP for each common share previously held by ABP in FluroTest at a deemed price of $0.37 per Share.
Prior to the Transaction, ABP held 16,417,500 Shares, representing 20.54% of FluroTech's 79,905,181 issued and outstanding Shares. As a result of the Transaction, ABP now has beneficial ownership of 28,629,108 Shares, representing approximately 23.73% of the FluroTech's 120,610,542 issued and outstanding Shares.
This news release is issued pursuant to National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. A copy of the early warning report will appear with 396's documents on the System for Electronic Document Analysis and Retrieval at www.sedar.com.
For further information or to request a copy of the early warning report, please contact:
Alberta BioPhotonics
Attention: Danny Dalla-Longa
Telephone: 403-680-0644
Well this is total bs
substantial increase
there are now 120,610,542 common shares outstanding
just under 2 million shares have traded this week... my guess is it's a small amount of profit taking by investors who bought shares in January at .135 (TEST)
in January warrants were announced at .22 (TEST), and last month options were offered at .45 (TEST)
I think the future is bright, and believe the share price will be up substantially in a few weeks
MAY 26 update
https://backend.otcmarkets.com/otcapi/company/financial-report/285361/content
Here are highlights:
in 2020 and Q1 2021, FluroTech implemented significant cost saving measures
the Company is in later stage discussions with a US based company for the sale of the cannabis testing business and both parties are evaluating the opportunity
FluroTest has developed a proof-of-concept PDP ( Pandemic Defense Platform ) prototype, the testing method and device is in research and development, and accordingly, the Company is not making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus
Q3 2020, FluroTest completed successful proof of concept studies on its COVID-19 antigen immunoassay
FluroTest’s PDP is unique because it targets active infections evidenced by the presence of live viral particles
The PDP is one of the only automated, high-throughput, saliva-based antigen tests currently in research and development
FluroTech has identified six clinical study partners, built a robust and skilled advisory board and is moving forward from proof of concept to product certification
The PDP is currently preparing for clinical trials which is required to collect the data for the FDA approval submission
3/31/21 Total current assets.. 1,876,535
3/31/21 Total liabilities....... 231,508
Nope offering share became available
Tick tock $FLURF
1-minute, ‘non-invasive’ Covid breath test authorized for deployment in Singapore
A one-minute Covid-19 breath test has received provisional authorization in Singapore, where it will be used to test people coming into the country from Malaysia.
The National University of Singapore’s Breathonix test – which was developed from “cancer detection technology” – can detect Volatile Organic Compounds in a person’s breath to see if they are healthy or not, researchers say, though the test will also be used alongside more traditional antigen rapid testing.
In partnership with the Singapore Ministry of Health, Breathonix will first deploy its testing at the Tuas Checkpoint, which connects Singapore and Malaysia.
Breathonix’s test was previously trialed at Changi Airport, the National Centre for Infectious Diseases, and in Dubai, and the breathalyzer technology is unlikely to cause any cross-contamination, according to its founders.
“Our breath test is non-invasive. Users only need to breathe out normally into the disposable mouthpiece provided, so there will not be any discomfort,” Breathonix CEO Dr. Jia Zhunan said. “Cross-contamination is unlikely as the disposable mouthpiece has a one-way valve and a saliva trap to prevent inhalation or saliva from entering the machine.”
The test will likely be the fastest in the world upon its rollout and could be a gamechanger in places where fast results are necessary, including airports and borders.
Merger complete !!! Let’s gooooo
Ready for lift off
FluroTest Provides Clinical Trial Update for High Volume COVID-19 Rapid Antigen Testing System
PR Newswire
CALGARY, AB, May 10, 2021
Clinical Trial Progresses Across Six Clinical Site Locations Throughout the US
CALGARY, AB, May 10, 2021 /PRNewswire/ - FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces the next phase of its ongoing clinical trials with its trial partner Toolbox Medical Innovations ("Toolbox").
The Company is pleased to report that approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals, are being identified from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. The data collected from this and the upcoming pilot program with California-based Total Testing Solutions (previously announced in the Company's news release dated May 3, 2021) will be used to support submissions for Emergency Use Authorization ("EUA") from the U.S. Food and Drug Administration ("FDA") and Health Canada for an Interim Order Authorization.
Toolbox has expertise in helping organizations surpass each step of the submission process from clinical study design and development, all the way up to regulatory planning and support, allowing them to provide a fast and efficient path to FDA and other approvals for diagnostic products. The 600-patient trial will be one of the most extensive conducted to date for FDA / Health Canada submissions.
Dr. Melina Cimler, Ph.D., CEO and Founder of PandiaDx LLC, remains actively engaged by FluroTest for regulatory guidance and services. A senior quality, regulatory, and in vitro diagnostic device expert with more than 30 years of experience in the life science and FDA-regulated diagnostic industry, Dr. Cimler is in close contact with key decision makers and is monitoring recent testing initiatives such as the Biden Administration's proposal to spend $10 Billion USD to carry out COVID-19 testing to help speed school reopenings and maintain normal attendance levels. FluroTest's technology is particularly suited to such initiatives and remains one of its target markets.
"I am exceptionally proud and excited by the results that our team, including an A-list partner and advisor network, have produced over the course of the last few months in particular," said Bill Phelan, CEO, FluroTest Diagnostics Systems. "Navigating the evolving new normal requires innovative high throughput approaches that provide business and societal benefits on a world-wide scale. Despite global supply chain challenges, evolving regulations, and a society and economy in flux, we are still on track for meeting our targets for regulatory submissions and full-scale commercialization in Q2/Q3 2021. I believe FluroTest will soon emerge as society's point of access testing standard, and our supporters will benefit as a result."
FluroTest's high-volume antigen system is designed to facilitate very fast and accurate point of access testing of individuals by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. High-risk pandemic environments supported will include athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, manufacturing facilities, schools and colleges, hospitals and large healthcare facilities, transportation and distribution hubs and other large businesses.
Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.
About FluroTech (TSXV: TEST) (OTCQB: FLURF)
The goal of FluroTech's research and technology is to develop detection methods which are high speed, sensitive, specific and easy-to-use. By combining FluroTech's proprietary spectroscopy-based technology with laboratory robotics automation and cloud computing, FluroTech, through the application of its technology and investment in FluroTest Diagnostics Systems Ltd. ("FluroTest"), the interests in which have been disclosed in previous press releases, has created a unique solution addressing the current and future pandemics. Using technology that was first developed at the University of Calgary, the FluroTest SARS-CoV-2 test is designed to identify patients with active virus infection; this is not necessarily the case for most of the currently approved tests that are meant to identify patients with SARS-CoV-2 nucleic acid.
About FluroTest Diagnostic Systems Ltd.
FluroTest, a diagnostics technology leader in surge-scale rapid antigen testing for the detection of SARS-CoV2 and other pathogens, is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly accurate testing for significant numbers of people. Unlike individual or low-throughput tests, FluroTest's system is designed to be well-suited for high-traffic, high-risk pandemic environments including schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations. Created to support executive business continuity efforts and public well-being, the system combines and leverages the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing -- processing thousands of tests per hour while delivering accurate, digitally verifiable results to a test taker's mobile device within 5 minutes. To learn more, visit FluroTest.com.
Cautionary Statement Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer's business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer's perspective financial performance or financial position. The forward-looking information in this news release includes disclosure about the ability of the Company's testing devices to accurately and quickly detect COVID-19 and to process large numbers of samples in short time frames, the benefits of and demand for the Company's testing devices, its efforts to obtain approval of the FDA and Health Canada, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Diagnostics Systems Ltd which owns a 100% interest in FluroTest LLC. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the ability to obtain FDA and Health Canada approvals, the demand for its COVID-19 testing devices and their ability to perform as expected, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Diagnostics Systems Ltd which owns a 100% interest in FluroTest LLC and to obtain the regulatory approvals required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
FDA APPROVAL PLEASE
Another mou .... this getting ready to explode
COME ON FDA WE NEED HIGH LEVEL OUTPUT TESTING
This stock could change lives literally...
Yeah, the world continues to sleep on this ... giant-in-the-making
Hell ya ... testing in 5 states
yep... this is big
the part I like best is: "we are still on track for meeting our targets for regulatory submissions and full-scale commercialization in Q2/Q3 2021. "
https://www.prnewswire.com/news-releases/flurotest-provides-clinical-trial-update-for-high-volume-covid-19-rapid-antigen-testing-system-301287128.html
big news out
100% agreed
More great news.
I really enjoy seeing back to back PRs with important stuff. No fluff here! This technology could put an end to lock downs and experimental jabs, and disarm the need for covid passports. Another PR or two along with the beginning of trials and the sp will soar past the all time high.
FluroTest Prepares to Detect SARS-CoV-2 Variants of Concern with High-Throughput COVID-19 Testing Platform
Press Release | 05/04/2021
FluroTest Prepares to Detect SARS-CoV-2 Variants of Concern with High-Throughput COVID-19 Testing Platform
PR Newswire
CALGARY, AB, May 4, 2021
CALGARY, AB, May 4, 2021 /PRNewswire/ - FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce based on the data collected to date that the FluroTest platform will be capable of detecting the primary variants of concern now spreading across North America and fueling serious outbreaks around the world.
FluroTest Logo (CNW Group/FluroTech Ltd.)
Many of the variants of concern are mutations that alter the viral structure through the spike ("S") protein found on the molecular surface. FluroTest's antigen immunoassay detects the nucleocapsid ("N") protein, which is found deep within the virus' structure and, so far, remains relatively unaffected by major mutations in the main variants of concern. FluroTest works with the world's leading reagent suppliers of the antibody pairs that are used in the Pandemic Defense Platform Immunoassay. Additionally, they have confirmed that the antibody pairs FluroTest uses can detect the UK, South African and Brazilian variants and they continually collect data on emerging variants of concern.
"We are pleased to work with suppliers that have extensive biologics experience to give us the confidence that we will be able to detect the variants of concern," said FluroTech R&D Director and Senior Scientist, Dr. Mauricio Arias. "As new variants emerge at an increasing pace, testing will become much more important worldwide. I believe many countries will follow the UK's strategy of fast, frequent and easy testing."
Variants of the SARS-CoV-2 virus first identified in the UK, South Africa, and Brazil appear to be more transmissible than the original wild viral strain first identified in 2019. The increased frequency and spread of these variants of concern has solidified the importance of widespread screening and surveillance, two of many uses for the FluroTest Pandemic Defense Platform. Leaders from FluroTest's target industries have openly stated that vaccine passports alone will not be sufficient. Accurate and verifiable testing is also extremely important to reopening the economy.
"The most common consensus is that vaccines alone will not be enough to end the pandemic in light of the rapid mutations of SARS-CoV-2," added Danny Dalla-Longa, CEO of FluroTech. "By identifying people who are actively contagious and preventing them from entering sports stadiums, airplanes, cruise ships and schools, we can actively return to normal pre-pandemic life safely. This can only be done with strict restrictions in addition to vaccination, or by fast and frequent testing. Just as with 9-11 and airport security, international pathogen safety protocols will be evolving. FluroTest believes that we are that next evolution."
FluroTest's system is designed to facilitate fast and accurate point-of-access testing of individuals by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. High-risk pandemic environments supported will include schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations.
Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.
About FluroTest Diagnostic Systems
FluroTest, a first mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly accurate testing for significant numbers of people. Unlike individual or low-throughput tests, FluroTest's system is designed to be well-suited for high-traffic, high-risk pandemic environments including schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations. Created to support executive business continuity efforts, the system combines and leverages the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing -- processing thousands of tests per hour while delivering accurate, digitally verifiable results to a test taker's mobile device within 5 minutes. To learn more, visit FluroTest.com
About FluroTech (TSXV: TEST) (OTCQB: FLURF)
FluroTest is a subsidiary of FluroTech. The goal of FluroTech's research and technology is to develop detection methods which are sensitive, specific and easy-to-use. By combining FluroTech's proprietary spectroscopy-based technology with laboratory robotics automation and cloud computing, FluroTech, through the application of its technology and investment in FluroTest, has created a unique solution addressing the current and future pandemics. Using technology that was first developed at the University of Calgary, the FluroTest SARS-CoV-2 test is designed to identify patients with active virus infection; this is not necessarily the case for most of the currently approved tests that are meant to identify patients with SARS-CoV-2 nucleic acid. FluroTech's laboratory is led by Dr. Elmar Prenner, the original developer of the technology. Dr. Prenner serves as senior science advisor of FluroTech and brings over 28 years of expertise in fluorescence spectroscopy. To learn more, visit FluroTech.com
Cautionary Statement Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer's business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer's perspective financial performance or financial position. The forward-looking information in this news release includes disclosure about the ability of the Company's testing devices to accurately and quickly detect COVID-19 and to process large numbers of samples in short time frames, the benefits of and demand for the Company's testing devices, its efforts to obtain approval of the FDA and Health Canada, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Diagnostics Systems Ltd which owns a 95% interest in FluroTest LLC. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the ability to obtain FDA and Health Canada approvals, the demand for its COVID-19 testing devices and their ability to perform as expected, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Diagnostics Systems Ltd which owns a 95% interest in FluroTest LLC and to obtain the regulatory approvals required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporation's Annual Information Form under the heading "Risk Factors", the failure to develop and commercialize its testing devices in a timely manner or at all, the failure to recognize the anticipated benefits from the devices, the failure to obtain FDA or Health Canada approval for its products, the risk that regulatory approvals will not be received and the risk that changing circumstances will result in the decrease in demand for FluroTest's products. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.
The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/flurotest-prepares-to-detect-sars-cov-2-variants-of-concern-with-high-throughput-covid-19-testing-platform-301282628.html
SOURCE FluroTech Ltd.
I added more ... another possible sports team ... :)
"FluroTest and TTS will launch...."
https://www.newswire.ca/news-releases/flurotest-diagnostics-systems-and-total-testing-solutions-sign-pilot-program-mou-to-bring-first-high-volume-sars-cov-2-testing-system-to-california-839405892.html
https://www.prnewswire.com/news-releases/flurotest-diagnostics-systems-and-total-testing-solutions-sign-pilot-program-mou-to-bring-first-high-volume-sars-cov-2-testing-system-to-california-301281753.html
An optimistic agreement, but without a specified date for FDA testing to begin. Could it come in the next couple weeks?
On March 4 an agreement was signed with "Toolbox Medical Innovations to carry out clinical trials of the FluroTest pandemic response platform"
"Toolbox is well-versed in simplifying and expediting the complex FDA approval procedures."
https://flurotest.com/globe-newswire/flurotech-partners-with-toolbox-medical-innovations-for-clinical-trial-of-mass-scale-covid-19-testing-platform/
Has this begun?
Company is making positive moves & certainly partnering with the right people & companies, both in the U.S. & in Canada, to get this done. Good things to come!
Also , in latest video they talk about international ...
So this could end up being every where ..
Is they use this in nba. , nfl , airports yeah that might be low ..
Imagine the day after it’s on the news :)
20 times current price ...
A 20 banger ? Do you mean 20 times the current sp, or $20 ?
20 x .30 = $6. Yes, when FDA says GO! this will take off. Didn't they say FDA testing in April? A few weeks from now we could be grinning ear to ear.
I envision this easily jumping to $2-3 within weeks of approval, and I can see $6 a share as very realistic by Q4.
Could this eventually get to $20 a share? The current market cap is 22.3 million, so you're looking at a future with a market cap of about 1.5 billion.
What do you think? Reasonable?
People sleeping on this . If fda approves and we get Fenway park .... this stock will be all over the news and trading $20 easy ....imho
Right there with you, haven't changed a thing, just waiting patiently
I’m loading the boat either I’m wrong or 20 banger ...
get them test done
Sounds good
Yep, just hangin' out
Unfortunately it seems my prediction that the vaccines aren't going to cut it is proving out
So, we should be good to go still. Waiting for more update news.
Anyone still here ... Thinking we see a major move if test go well.
Sry, I wasn't watching. Still waiting for more news.
Usually it is some circuit breaker thing, too big a move too fast.
Did we figure it out ?
Added some more ... covid coming back , should make this hot again ... sad to say
These so called vaccines do not claim to halt transmission like a real vaccine
They only reduce impact, from what I've been reading
So everyone still needs tested indefinitely
It could be a while before everybody wakes up to that fact.
Something the other day, somebody came up with a "tamiflu-like" medicine for this, THAT seems to work well
Put the money in the bag
Maybe even at the airport for people who choose not to get vaccinated..?
Announced merger with flurotech .
Anyone here know the deal with the trading halt, and I guess apparent resumption today? @lightrock - you got any insight?
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
240
|
Created
|
01/07/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |